Skip to content

Integra Lifesciences

US · IART #3240 by market cap
13.25 -0.30 -2.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 13.21 -2.51%
After-hours 12.99 -1.96%
19.8511.8413.252026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IART?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -0.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 10.1% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall F
ValuationGrowthProfitMomentumHealthAnalyst
Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 77.9x Better than 5%
Forward P/E 15.7x Better than 53%
Price / Sales 0.7x Better than 86%
P/E vs own 5-yr range 99th pctl Better than 3%
Growth D

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 1.6% Better than 33%
Net income CAGR (3Y) -20.3% Better than 18%
Free cash flow CAGR (3Y) -61.6% Better than 2%
Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 50.9% Better than 64%
Operating margin 1.1% Better than 23%
Net margin -31.6% Better than 10%
Return on equity -39.9% Better than 10%
Return on invested capital -13.8% Better than 16%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -20.8% Better than 30%
6-month return -12.3% Better than 37%
12-month return (ex latest month) -1.1% Better than 33%
Distance below 52-week high 35.3% Better than 34%
Financial Health D+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.5x Better than 67%
Debt to assets 56.4% Better than 10%
Interest coverage -5.5x Better than 16%
Free cash flow / net income 107.9% Better than 44%
Analyst View D

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 14.3% Better than 7%
Upside to average target 13.2% Better than 19%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.99%
1M -0.60%
3M -20.13%
6M -13.91%
YTD +6.68%
1Y +19.91%
3Y -65.76%
5Y -80.76%

Key statistics

Price & volume

Prev close
13.55
Open
13.38
Day range
13.16 - 13.79
Avg price
13.37
Volume
828.62K
Turnover
11.07M
Amplitude
4.63%
52-week range
8.70 - 20.49

Valuation

P/E
-1.97
P/E (TTM)
77.94
P/B
0.97
EPS
-6.74
Net profit
-524.38M
Net assets
1.07B

Share structure

Market cap
1.03B
Float cap
782.21M
Shares out
77.80M
Float shares
59.04M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 39% of range
8.70 20.49

35.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.15M net over the window

Short interest

Shares short
7.90M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Integra Lifesciences (IART)?

Integra Lifesciences last traded at 13.25. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Integra Lifesciences's market cap?

About 1.03B.

What is the P/E ratio of Integra Lifesciences?

The trailing twelve-month P/E is 77.94. The Valuation tab shows it against the stock's own five-year range.

Does Integra Lifesciences pay a dividend?

Integra Lifesciences does not currently pay a regular dividend.

Is Integra Lifesciences a buy according to analysts?

The consensus of 7 analysts is a Hold rating, with an average 12-month price target of 15.00, which implies 13.2% upside from the current price. This is not investment advice.

What is Integra Lifesciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Integra Lifesciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Integra Lifesciences discussion 0 comments

Add a comment